European Archives - Page 1359 of 1423 - European Medical Journal

EMJ

Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…

EMJ

Phase 2 MMY2002 trial of daratumumab in myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca…

EMJ

Results of the phase 3 ELOQUENT-2 trial

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA…

EMJ

Results of the phase 3 PERSIST-1 trial of pacritinib for myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…

EMJ

Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…

EMJ

DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse

Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882…

EMJ

Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML

The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free…

The crucial roles of GFI1B in platelet development

The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the…

Pacritinib therapy led to symptom improvement in myelofibrosis

The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more…

Treatment and outcome of CML patients from the EUTOS population-based registry

The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).